Urine Metabolites Associated with the Dietary Approaches to Stop Hypertension (DASH) Diet: Results from the DASH‐Sodium Trial

ScopeSerum metabolomic markers of the Dietary Approaches to Stop Hypertension (DASH) diet are previously reported. In an independent study, the similarity of urine metabolomic markers are investigated.Methods and ResultsIn the DASH‐Sodium trial, participants are randomly assigned to the DASH diet or control diet, and received three sodium interventions (high, intermediate, low) within each randomized diet group in random order for 30 days each. Urine samples are collected at the end of each intervention period and analyzed for 938 metabolites. Two comparisons are conducted: 1) DASH‐high sodium (n = 199) versus control‐high sodium (n = 193), and 2) DASH‐low sodium (n = 196) versus control‐high sodium. Significant metabolites identified using multivariable linear regression are compared and the top 10 influential metabolites identified using partial least‐squares discriminant analysis to the results from the DASH trial. Nine out of 10 predictive metabolites of the DASH‐high sodium and DASH‐low sodium diets are identical. Most candidate biomarkers from the DASH trial replicated. N‐methylproline, chiro‐inositol, stachydrine, and theobromine replicated as influential metabolites of DASH diets.ConclusionsCandidate biomarkers of the DASH diet identified in serum replicated in urine. Replicated influential metabolites are likely to be objective biomarkers of the DASH diet.